Loading stock data…
ALEC
$2.05-0.05 (-2.38%)
Market ClosedLast close May 11
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alector, Inc. in the Healthcare sector is trading at $2.05. The stock is currently 40% below its 52-week high of $3.40, remaining 1.9% below its 200-day moving average. Technical signals show neutral RSI of 30 and bearish MACD signal, explaining why ALEC maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 30) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.05
Potential Upside
5%
Whystock Fair Value$2.15
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Hold
Mean target$3.63+76.8%
Range$1.50 – $6.00
Fundamentals
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treatin...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$269.28M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.58
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-376.16%
Volume
Today's trading volume
382,815
Recent News
Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates
Alector (ALEC) delivered earnings and revenue surprises of +40.00% and -65.13%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes (ALKS) Reports Q1 Loss, Beats Revenue Estimates
Alkermes (ALKS) delivered earnings and revenue surprises of +30.31% and +9.50%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
GSK Juggles Alzheimer’s Setback And Leadership Shift With Product Progress
GSK (LSE:GSK) and Alector have discontinued their phase 2 trial of an Alzheimer's drug candidate after the study did not meet efficacy goals. The decision effectively ends a high profile collaboration in neurodegenerative research between the two companies. Separately, GSK received UK approval for Lynavoy (linerixibat) to treat primary biliary cholangitis. The company has also appointed Roanne Parry as Chief People Officer, a move that may shape its global people and culture agenda. GSK,...
How The Alector (ALEC) Narrative Is Shifting Toward BBB Shuttle Programs And Execution Risk
Alector’s refreshed analyst narrative comes with $6 price targets that are presented as more closely aligned with the company’s current therapeutic pipeline and BBB shuttle focus. Research notes link these $6 targets to a cleaner story after the frontotemporal dementia trial, with a stronger spotlight on neurodegeneration mechanisms and protein engineering strengths, alongside ongoing execution and clinical risks. As you read on, you will see how this evolving setup might shape your own view...